Биологическая активность
BMS-582949 is a мощный and селективный P38 mitogen-activated protein киназы (P38 MAPK) ингибитор. BMS-582949 is currently under Phase II clinical trials for the treatment of inflammatory diseases. One clinical study showed that, in stable atherosclerosis, 12 weeks of treatment with BMS-582949 did not reduce arterial inflammation or hs-CRP compared to placebo, whereas intensification of statin therapy significantly decreased arterial inflammation. p38α MAP киназы plays a crucial role in regulating the biosynthesis of many inflammatory cytokines including TNFα and IL-1β.
Оригинал на английском
BMS-582949 is a potent and selective P38 mitogen-activated protein kinase (P38 MAPK) inhibitor. BMS-582949 is currently under Phase II clinical trials for the treatment of inflammatory diseases. One clinical study showed that, in stable atherosclerosis, 12 weeks of treatment with BMS-582949 did not reduce arterial inflammation or hs-CRP compared to placebo, whereas intensification of statin therapy significantly decreased arterial inflammation. p38α MAP kinase plays a crucial role in regulating the biosynthesis of many inflammatory cytokines including TNFα and IL-1β.
Химические свойства
- CAS №
- 912806-16-7
- Брутто-формула
- C₂₂H₂₇ClN₆O₂
- Мол. масса
- 442.95 г/моль
- Синонимы
- BMS-582949; BMS 582949; BMS582949; PS-540446; PS 540446 и ещё 1
Безопасность и документация
Только для научно-исследовательского применения. Не предназначено для использования у пациентов или в качестве лекарственного средства.